期刊
EUROPEAN JOURNAL OF CANCER
卷 42, 期 18, 页码 3127-3139出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2006.09.015
关键词
angiogenesis inhibitors; antibodies; tyrosine kinase inhibitors; VEGF; side-effects; treatment
类别
Clinical experience with vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors is rapidly increasing, and some compounds have already been approved for regular anticancer treatment. Apart from their activity, much attention has been focussed on the clinical toxicity profile of these compounds. This review describes the most frequently occurring side-effects of both antibodies and tyrosine kinase inhibitors and discusses some of the underlying mechanisms. Some practical guidelines for treatment of the side-effects are given. (c) 2006 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据